Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock Name3D Medicines
Stock Code01244
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是一家成立於2014年的生物醫藥公司,致力於為癌症患者,尤其是那些需要長期治療的患者研發腫瘤藥物。核心業務模式是通過聯合合作開發、許可引進及自主發現等方式,開發及商業化腫瘤產品及候選藥物。
Listing Date2022-12-15
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國 上海市 浦東新區 芙蓉花路118號 11號樓
Business Address (Hong Kong)香港 德輔道中188號 金龍中心14樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Website3d-medicines.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism 18A生物科技
Offer PriceHK$ 24.98 / shares
Offer Price RangeFinal offer price only, no range
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 0.001 / shares
Offer Period2022-11-29 to 2022-12-07
Global Offering Shares16,350,000 shares
HK Public Offer Shares (Initial)1,635,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)14,715,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO255,642,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share57.4%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 408,423,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 821.8M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +1082%

Valuation & Financials

Market Cap (at Offer Price)HK$ 6,385,937,160
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20202021
Revenue 60,260161,062
Cost of sales -4,277-11,458
Gross profit 55,983149,604
Other income and gains, net 2,33721,480
Selling and distribution expenses 0-103,567
Administrative expenses -40,528-46,631
Net finance costs -8,058-740
Profit before tax -635,380-1,461,825
Income tax expense 00
Profit for the year -635,380-1,461,825
Profit attributable to owners -635,380-1,434,092
Balance Sheet
Item 202020212022-05
Cash and cash equivalents 414,261774,306
Trade and bills receivables 065,004
Inventories 013
Total current assets 461,755919,227
Total assets 496,2161,060,293
Total current liabilities 315,0083,248,045
Total liabilities 1,766,0313,332,855
Total equity -1,269,815-2,272,562
Equity attributable to owners -1,269,815-2,238,011
Interest-bearing borrowings 3,52200
Cash Flow Statement
Item 202020212022-05
Net cash from operating activities -278,329-377,079
Net cash from investing activities -20,480-98,871
Depreciation of PP&E 1,1533,7503,331
Depreciation of right-of-use assets 2,2188,7575,442
Amortisation of intangible assets 08442
Purchase of PP&E -11,147-43,872-16,248
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 31.45
First Day OpenHK$ 29.0
First Day Change25.90%
First Day Volume1515300.0
First Day Turnover44431600.0
Use of Proceeds
1、約55%,或138.1百萬港元,將用于公司的核心產品恩沃利單抗; 2、約25%,或62.8百萬港元,將用于公司的其他候選藥物; 3、約10%,或25.1百萬港元,將用于建造公司位于江蘇省徐州市的內部生產設施及采購新機器、儀器和設備; 4、約10%,或25.1百萬港元,將用于公司的一般企業及營運資金用途。

Underwriting Syndicate

Joint Sponsors (2)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 中信建投(国际)融资有限公司 CE BAU112
Overall Coordinators (3)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 中信建投(国际)融资有限公司 CE BAU112 CNCB (Hong Kong) Capital Limited CE AEQ982
Joint Bookrunners (8)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 中信建投(国际)融资有限公司 CE BAU112 CNCB (Hong Kong) Capital Limited CE AEQ982 建银国际金融有限公司 CE AJO225 XinKong International Securities Limited CE ACV085 Livermore Holdings Limited CE BJN764 农银国际证券有限公司 CE ACX411 老虎证券(香港)环球有限公司 CE BMU940
Joint Lead Managers (13)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 中信建投(国际)融资有限公司 CE BAU112 CNCB (Hong Kong) Capital Limited CE AEQ982 建银国际金融有限公司 CE AJO225 XinKong International Securities Limited CE ACV085 Livermore Holdings Limited CE BJN764 农银国际证券有限公司 CE ACX411 老虎证券(香港)环球有限公司 CE BMU940 SDHG International Securities Limited CE ADY241 Lego Securities Limited CE BIE918 VALUABLE CAPITAL LIMITED CE AUL711 富途证券国际(香港)有限公司 CE AZT137 VICTORY SECURITIES COMPANY LIMITED CE ABN091

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Harvest International Premium Value (Secondary Market) Fund SPC 78,449,690 HKD — 19.21% — 6 months 2023-06-15
2 Mobilewise Limited 31,374,880 HKD — 7.68% — 6 months 2023-06-15
3 好赞资产管理有限公司 78,449,690 HKD — 19.21% — 6 months 2023-06-15
4 徐州经济技术开发区(香港)投资有限公司 46,325,410 HKD — 11.34% — 6 months 2023-06-15

Directors & Management

PositionChinese nameEnglish Name
Chairman龔兆龍—
Company Secretary夏芳、李菁怡—
No director data available.

Major Shareholders

Major Shareholders & Holdings龔兆龍博士(透過Dragon Prosper及股份激勵平台)持有約31.06%股份(緊接全球發售前),先聲藥業集團持股約9.63%,深圳倚鋒持股約5.77%。
About this page

This page shows 3D Medicines (01244) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect